Cargando…

COVID-19-related health outcomes in people with primary immunodeficiency: A systematic review

A better understanding of COVID-19 in people with primary immunodeficiency (PI), rare inherited defects in the immune system, is important for protecting this population, especially as population-wide approaches to mitigation change. COVID-19 outcomes in the PI population could have broader public h...

Descripción completa

Detalles Bibliográficos
Autores principales: Drzymalla, Emily, Green, Ridgely Fisk, Knuth, Martha, Khoury, Muin J., Dotson, W. David, Gundlapalli, Adi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Academic Press 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9375253/
https://www.ncbi.nlm.nih.gov/pubmed/35973637
http://dx.doi.org/10.1016/j.clim.2022.109097
_version_ 1784767926261252096
author Drzymalla, Emily
Green, Ridgely Fisk
Knuth, Martha
Khoury, Muin J.
Dotson, W. David
Gundlapalli, Adi
author_facet Drzymalla, Emily
Green, Ridgely Fisk
Knuth, Martha
Khoury, Muin J.
Dotson, W. David
Gundlapalli, Adi
author_sort Drzymalla, Emily
collection PubMed
description A better understanding of COVID-19 in people with primary immunodeficiency (PI), rare inherited defects in the immune system, is important for protecting this population, especially as population-wide approaches to mitigation change. COVID-19 outcomes in the PI population could have broader public health implications because some people with PI might be more likely to have extended illnesses, which could lead to increased transmission and emergence of variants. We performed a systematic review on COVID-19-associated morbidity and mortality in people with PI. Of the 1114 articles identified through the literature search, we included 68 articles in the review after removing 1046 articles because they were duplicates, did not involve COVID-19, did not involve PI, were not in English, were commentaries, were gene association or gene discovery studies, or could not be accessed. The 68 articles included outcomes for 459 people with PI and COVID-19. Using data from these 459 people, we calculated a case fatality rate of 9%, hospitalization rate of 49%, and oxygen supplementation rate of 29%. Studies have indicated that a number of people with PI showed at least some immune response to COVID-19 vaccination, with responses varying by type of PI and other factors, although vaccine effectiveness against hospitalization was lower in the PI population than in the general population. In addition to being up-to-date on vaccinations, current strategies for optimizing protection for people with PI can include pre-exposure prophylaxis for those eligible and use of therapeutics. Overall, people with PI, when infected, tested positive and showed symptoms for similar lengths of time as the general population. However, a number of people with X-linked agammaglobulinemia (XLA) or other B-cell pathway defects were reported to have prolonged infections, measured by time from first positive SARS-CoV-2 test to first negative test. As prolonged infections might increase the likelihood of genetic variants emerging, SARS-CoV2 isolates from people with PI and extended illness would be good candidates to prioritize for whole genome sequencing.
format Online
Article
Text
id pubmed-9375253
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Academic Press
record_format MEDLINE/PubMed
spelling pubmed-93752532022-08-15 COVID-19-related health outcomes in people with primary immunodeficiency: A systematic review Drzymalla, Emily Green, Ridgely Fisk Knuth, Martha Khoury, Muin J. Dotson, W. David Gundlapalli, Adi Clin Immunol Review Article A better understanding of COVID-19 in people with primary immunodeficiency (PI), rare inherited defects in the immune system, is important for protecting this population, especially as population-wide approaches to mitigation change. COVID-19 outcomes in the PI population could have broader public health implications because some people with PI might be more likely to have extended illnesses, which could lead to increased transmission and emergence of variants. We performed a systematic review on COVID-19-associated morbidity and mortality in people with PI. Of the 1114 articles identified through the literature search, we included 68 articles in the review after removing 1046 articles because they were duplicates, did not involve COVID-19, did not involve PI, were not in English, were commentaries, were gene association or gene discovery studies, or could not be accessed. The 68 articles included outcomes for 459 people with PI and COVID-19. Using data from these 459 people, we calculated a case fatality rate of 9%, hospitalization rate of 49%, and oxygen supplementation rate of 29%. Studies have indicated that a number of people with PI showed at least some immune response to COVID-19 vaccination, with responses varying by type of PI and other factors, although vaccine effectiveness against hospitalization was lower in the PI population than in the general population. In addition to being up-to-date on vaccinations, current strategies for optimizing protection for people with PI can include pre-exposure prophylaxis for those eligible and use of therapeutics. Overall, people with PI, when infected, tested positive and showed symptoms for similar lengths of time as the general population. However, a number of people with X-linked agammaglobulinemia (XLA) or other B-cell pathway defects were reported to have prolonged infections, measured by time from first positive SARS-CoV-2 test to first negative test. As prolonged infections might increase the likelihood of genetic variants emerging, SARS-CoV2 isolates from people with PI and extended illness would be good candidates to prioritize for whole genome sequencing. Academic Press 2022-10 2022-08-13 /pmc/articles/PMC9375253/ /pubmed/35973637 http://dx.doi.org/10.1016/j.clim.2022.109097 Text en Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.
spellingShingle Review Article
Drzymalla, Emily
Green, Ridgely Fisk
Knuth, Martha
Khoury, Muin J.
Dotson, W. David
Gundlapalli, Adi
COVID-19-related health outcomes in people with primary immunodeficiency: A systematic review
title COVID-19-related health outcomes in people with primary immunodeficiency: A systematic review
title_full COVID-19-related health outcomes in people with primary immunodeficiency: A systematic review
title_fullStr COVID-19-related health outcomes in people with primary immunodeficiency: A systematic review
title_full_unstemmed COVID-19-related health outcomes in people with primary immunodeficiency: A systematic review
title_short COVID-19-related health outcomes in people with primary immunodeficiency: A systematic review
title_sort covid-19-related health outcomes in people with primary immunodeficiency: a systematic review
topic Review Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9375253/
https://www.ncbi.nlm.nih.gov/pubmed/35973637
http://dx.doi.org/10.1016/j.clim.2022.109097
work_keys_str_mv AT drzymallaemily covid19relatedhealthoutcomesinpeoplewithprimaryimmunodeficiencyasystematicreview
AT greenridgelyfisk covid19relatedhealthoutcomesinpeoplewithprimaryimmunodeficiencyasystematicreview
AT knuthmartha covid19relatedhealthoutcomesinpeoplewithprimaryimmunodeficiencyasystematicreview
AT khourymuinj covid19relatedhealthoutcomesinpeoplewithprimaryimmunodeficiencyasystematicreview
AT dotsonwdavid covid19relatedhealthoutcomesinpeoplewithprimaryimmunodeficiencyasystematicreview
AT gundlapalliadi covid19relatedhealthoutcomesinpeoplewithprimaryimmunodeficiencyasystematicreview